Long-term data are available for baricitinib in other indications – with integrated safety analyses up to 9.3 years. New data in severe AA examine 3-year efficacy outcomes with continued treatment in initial responders.

Hidradenitis suppurativa is a chronic and flaring skin disease. New pooled clinical trial data presented at EADV 2024 suggest targeted therapy with bimekizumab could help reduce flares.

Hidradenitis suppurativa is a debilitating condition with an inflammatory component – and a link to obesity. New data presented at EADV 2024 explore the role of modern weight-loss options to help improve quality of life and reduce flares.